Chapter 77

Sexual Dysfunction

Suetonia C. Palmer

Suetonia C. Palmer

Department of Medicine, University of Otago Christchurch, Christchurch, New Zealand

Search for more papers by this author
Marinella Ruospo

Marinella Ruospo

Sydney School of Public Health, University of Sydney, NSW, Australia

Search for more papers by this author
Valeria Saglimbene

Valeria Saglimbene

Sydney School of Public Health, University of Sydney, NSW, Australia

Search for more papers by this author
Giovanni F.M. Strippoli

Giovanni F.M. Strippoli

Department of Emergency and Organ Transplantation University of Bari, Bari, Italy

School of Public Health University of Sydney, Sydney, NSW, Australia

Search for more papers by this author
First published: 18 November 2022

Summary

This chapter examines the evidence for management of sexual dysfunction in adults with chronic kidney disease (CKD). Sexual dysfunction is multifactorial in CKD. The chapter lists the potential factors involved in the pathogenesis of sexual dysfunction for men with CKD that can guide clinical inquiry and examination, and investigation. It also lists the potential factors contributing to sexual dysfunction for women. Sexual dysfunction in men with CKD may be associated with low testosterone levels. Bromocriptine is a dopamine agonist that is used in the treatment of high prolactin levels and associated conditions including hypogonadism, amenorrhea, and infertility. Zinc deficiency may be a factor in gonadal dysfunction and is present in men with CKD. Vitamin E is prescribed for sexual dysfunction based on the potential role of oxidative stress in erectile dysfunction. Lower sexual activity and desire are uncoupled from life and partner satisfaction among dialysis and transplant patients and partners.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.